Edition:
United Kingdom

Gilead Sciences Inc (GILD.OQ)

GILD.OQ on NASDAQ Stock Exchange Global Select Market

77.37USD
20 Jul 2018
Change (% chg)

$0.32 (+0.42%)
Prev Close
$77.05
Open
$76.50
Day's High
$77.70
Day's Low
$76.49
Volume
2,536,705
Avg. Vol
2,347,802
52-wk High
$89.53
52-wk Low
$64.27

Select another date:

Fri, Jun 29 2018

Photo

Rival Novartis, Gilead CAR-T therapies win European panel recommendation

ZURICH Rival cancer cell therapies from Swiss drugmaker Novartis and U.S.-based Gilead Sciences won a key recommendation from a European Medicines Agency panel, likely clearing their way for approval within months.

CORRECTED-UPDATE 1-Rival Novartis, Gilead CAR-T therapies win European panel recommendation

ZURICH, June 29 Rival cancer cell therapies from Swiss drugmaker Novartis and U.S.-based Gilead Sciences won a key recommendation from a European Medicines Agency panel, likely clearing their way for approval within months.

Rival Novartis, Gilead CAR-T therapies win European panel recommendation

Rival cancer cell therapies from Swiss drugmaker Novartis and U.S.-based Gilead Sciences won a key recommendation from a European Medicines Agency panel, likely clearing their way for approval within a couple of months.

Rival Novartis, Gilead CAR-T therapies win European panel recommendation

June 29 - Rival cancer cell therapies from Swiss drugmaker Novartis and U.S.-based Gilead Sciences won a key recommendation from a European Medicines Agency panel, likely clearing their way for approval within a couple of months.

GSK takes billion-dollar drug fight with Gilead to top AIDS meeting

LONDON GlaxoSmithKline is taking its fight with Gilead Sciences for dominance of the HIV market to the world's leading AIDS conference next month by showcasing detailed results from its new two-drug treatment.

GSK takes billion-dollar drug fight with Gilead to top AIDS meeting

LONDON GlaxoSmithKline is taking its fight with Gilead Sciences for dominance of the HIV market to the world's leading AIDS conference next month by showcasing detailed results from its new two-drug treatment.

GSK takes billion-dollar drug fight with Gilead to top AIDS meeting

LONDON, June 20 GlaxoSmithKline is taking its fight with Gilead Sciences for dominance of the HIV market to the world's leading AIDS conference next month by showcasing detailed results from its new two-drug treatment.

GSK's two-drug HIV treatment meets main goal in late stage studies

GlaxoSmithKline's two-drug treatment for HIV, the virus that causes AIDS, met its main goal in late stage studies, scoring key points in its rivalry with Gilead in the medical field.

GSK's two-drug HIV treatment meets main goal in late stage studies

GlaxoSmithKline's two-drug treatment for HIV, the virus that causes AIDS, met its main goal in late stage studies, scoring key points in its rivalry with Gilead in the medical field.

UPDATE 2-GSK's two-drug HIV treatment meets main goal in late stage studies

June 14 GlaxoSmithKline's two-drug treatment for HIV, the virus that causes AIDS, met its main goal in late stage studies, scoring key points in its rivalry with Gilead in the medical field.

Select another date: